Suche
Filter by content type
Filter by content year
BioNTech Announces Ryan Richardson to Step Down from the Management Board
Juli 17, 2025 - … chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house … The forward-looking statements in this press release are based on BioNTech’s current expectations and beliefs of … chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house …
BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer
Juni 12, 2025 - … development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech’s … medicines in oncology and infectious diseases based on messenger ribonucleic acid (“mRNA”). The all-stock … will bring together two highly complementary companies based in Germany and will build on BioNTech’s proven track …
BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
Juni 2, 2025 - … our antibody-drug conjugate programs and mRNA-based immunotherapies. We are dedicated to delivering truly … chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house … The forward-looking statements in this press release are based on BioNTech’s current expectations and beliefs of …
Pfizer and BioNTech Submit EMA Application for COVID-19 Vaccine Targeting LP.8.1 for 2025-2026 Season
Mai 28, 2025 - … strain. The COVID-19 vaccines by Pfizer and BioNTech are based on BioNTech’s proprietary mRNA technology and were … development, parturition or post-natal development. Based on data available with other vaccine variants, … including a monovalent COVID-19 vaccine candidate, based on the LP.8.1 strain, the submission of a regulatory …
BioNTech to Present Progress Across Diversified Oncology Pipeline at the 2025 ASCO Annual Meeting
Mai 27, 2025 - … chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house … BNT316/ONC-392 in advanced melanoma, and the mRNA-based RiboMab candidate BNT142 in CLDN6-positive advanced … The forward-looking statements in this press release are based on BioNTech’s current expectations and beliefs of …
BioNTech Expands Partnership with UK Government to Broaden Regional Research and Development Activities
Mai 20, 2025 - … of two new R&D centers, the first of which will be based in Cambridge and a second of which is currently being … in London, which will bring together the Company’s London-based teams and create new jobs in global and regional … patients have gained access to investigational mRNA-based cancer immunotherapies in the UK through the …
BioNTech Announces Appointment of Ramón Zapata to Management Board as Chief Financial Officer
Mai 5, 2025 - … chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house … or otherwise. These forward-looking statements are based on BioNTech’s current expectations and speak only as of … chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house …
BioNTech Announces First Quarter 2025 Financial Results and Corporate Update
Mai 5, 2025 - … lung cancer (NSCLC) mRNA Cancer Immunotherapies BNT116 is based on BioNTech’s fully owned, off-the-shelf FixVac … consideration of $800 million, plus additional performance-based payments of up to $150 million. BioNTech and Pfizer … chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house …
BioNTech to Present Clinical and Preclinical Data Across mRNA and Next-Generation Immuno-Oncology Priority Programs at AACR 2025
April 24, 2025 - … lung cancer (“NSCLC”) who were not eligible for platinum-based chemotherapy as first-line treatment. The preliminary … chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house … The forward-looking statements in this press release are based on BioNTech’s current expectations and beliefs of …
BioNTech to Report First Quarter 2025 Financial Results and Corporate Update on May 5, 2025
April 22, 2025 - … chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house … chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house … chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house …
